2 nd french/chinese symposium on research in
TRANSCRIPT
2ND FRENCH/CHINESE SYMPOSIUM ON RESEARCH IN ONCOLOGY
Monday, November 26, 2012 Cité Internationale Congress Center, Lyon
Room Saint Clair 1, 2nd Floor
IN PARTNERSHIP WITH
2
PROGRAM 08:30 – 09:00 Welcome Coffee
09:00 – 09:30 Introduction Hélène BLANCHARD – Rhône‐Alpes Region Representative Denis BOURGEOIS – Claude Bernard University Representative Thierry PHILIP – Cancéropôle CLARA Representative GAO Wei Qiang – Renji Stem Cell Center
09:30 – 10:45 Organization of Cancer Management: Clinical Research
Organization of the French Federation of Comprehensive Cancer Centers Christian CAILLIOT – Research Director UNICANCER
Presentation of the Cancer Research Center of Lyon Alain PUISIEUX – Cancer Research Center of Lyon
Prospective Cohort Study in Shanghai XIANG Yong Bing – Shanghai Cancer Institute
10:45 – 11:00 Coffee Break
11:00 – 12:00 Scientific Exchanges (15 min presentations) HEMATOLOGICAL MALIGNANCIES
Non Hodgkin’s Lymphoma: State of the Art and Perspective Gilles SALLES – Lyon University Hospital
Role of Glycolysis Pathway in the Pathogenesis of Non‐Hodgkin's Lymphomas and the Targeted Therapy WANG Ting – Renji Hospital, Jiao Tong University, Shanghai
Rnas Dysmaturation in Clonal Persistence, Leukemogenesis and Resistance to Treatment Eric WATTEL – Lyon University Hospital / Franck Mortreux–CR1 Inserm
Dynamic Interplay of PTKs and Phospahatases in Regulation of Adult Hematopoietic Stem/Progenitor Cells and Leukemogenesis ZHU He – Renji Stem Cells Research Center, Renji Hospital, Shanghai
12:00 – 13:30 Lunch Break
13:30 – 14:45 Organization of Cancer Management: Clinical Research Personnalized Medecine in Oncology: Organization of Molecular Diagnostics in France
Frédérique PENAULT LLORCA – Jean Perrin Cancer Center, Clermont Ferrand Pharmacology, Drug Development and Modelling
Benoit YOU – Lyon University Hospital Multidisciplinary Team: The Way Forward in Cancer Care
WANG Hong Xia – Renji Hospital, Jiao Tong University, Shanghai
3
PROGRAM – cont’d 14:45 – 15:45 Scientific Exchanges (15 min presentations) CANCER EPIDEMIOLOGY
Descriptive Epidemiology of Cancers in France: Organization, Activities and Some Results Nadine BOSSARD – Lyon University Hospital
The 40‐Year Transition of Cancer Incidence and Survival in Shanghai ZHENG Ying – Shanghai Center for Disease Control
INFLAMMATION Discovery of DKK1 as a Cancer Serum Protein Biomarker for the Diagnosis of Hepatocellular
Carcinoma and Translational Research QIN Wenxin – Shanghai Cancer Institute
Escape Mechanisms to Immunosurveillance in Breast Carcinoma Christophe CAUX – Léon Bérard Cancer Center, Lyon
15:45‐16:15 Coffee Break 16:15 – 17:15 Scientific Exchanges (15 min presentations) SOCIAL SCIENCES
How to Optimize Patient Follow‐Up: Social Sciences Perspectives and Community‐Based Research Marie PRÉAU – Lyon University Hospital
Ethical Issues in Cancer Research in China LU Qi – Renji Hospital, Association of Medical Ethics, Shanghai
CANCER STEM CELLS Role of BMPs in Cancer Stem Cells in Chronic Myeloid Leukemia and Luminal Breast Tumors
Véronique MAGUER SATTA – Cancer Research Center of Lyon Cancer Stem Cells, Therapeutic Resistance and Epithelial Mesenchymal Transition
GAO Wei Qiang – Renji Stem Cell Center 17:15 – 17:30 Concluding Remarks
Véronique TRILLET LENOIR – Lyon University Hospital GAO Wei Qiang – Renji Stem Cell Center
Organization:
Véronique TRILLET‐LENOIR – Lyon University Hospital Amaury MARTIN, Coralie KLEBER‐JEAN, Elise JACQUES – Cancéropôle Lyon Auvergne Rhône‐Alpes Virginie ROUAULT – Région Rhône‐Alpes Simon GUDIN – Lyonbiopôle/Entreprise Rhône‐Alpes International (ERAI)
4
Biography BOSSARD Nadine Gender: Female Title: Public Health Physician, MD, PhD Email: Nadine.bossard@chu‐lyon.fr Current Position: - Hospital Practioner – Associate Head of the Statistical Department of Lyon Hospital –France - Lecturer – University Claude Bernard Lyon 1. - Areas of activity: methods in cancer epidemiology (populational data), methods in clinical research for
various clinical fields (hospital data). Positions and Employment: From 2002: Hospital practioner (PH), Hospices Civils de Lyon
Currently in charge of the common French Cancer Registries database: partnership with the Institut National du Cancer, the Institut de Veille Sanitaire, and the French Cancer Registries (Francim network) for the National Cancer Epidemiological Surveillance Program. Activities in Epidemiological and Clinical research
1998‐2002: University Hospital Assistant ‐ Hospices Civils de Lyon – Biostatistic Department ‐ University Claude Bernard Lyon 1
1995‐1998: Methodologist‐Clinical project manager. Hospices Civils de Lyon – Oncology Research 1992‐1994 Public Health Physician ‐ Conseil Général du Rhône – Health promotion Department, Cancer
and sexual transmitted diseases 1990‐1992 Methodologist – Clinical project manager
Association pour la Promotion de la Recherche en Evaluation Thérapeutique 1985‐1990: Resident – 8 training courses in Public health and social medicine – Lyon Diplomas: 2004 Thèse science (PhD), Ecole doctorale E2M2, Claude Bernard University Lyon 1 (UCBL1) 2002 AEU de Communication scientifique médicale technique, (UCBL1) 1996 DES Complémentaire en Pharmacologie Clinique, (UCBL1)
DEA de Pharmacocinétique expérimentale et effets du médicament chez l’homme (UCBL1) 1990 Thèse de Médecine (MD) (UCBL1) 1990 Maîtrise de Pharmacologie (Msc), Dpt Biologie Humaine, (UCBL1) 1990 DES en Santé Communautaire et Médecine Sociale, (UCBL1) Publications (2010‐2012): - Colonna M, Mitton N, Schott AM, Remontet L, Olive F, Gomez F, Iwaz J, Polazzi S, Bossard N, Trombert
B. Joint use of epidemiological and hospital medico‐administrative data to estimate prevalence. Application to French data on breast cancer. Cancer Epidemiology. 2012;36:116‐121.
- Danieli C, Remontet L, Bossard N, Roche L, Belot A. Estimating net survival: the importance of allowing for informative censoring. Statistics in medicine. 2012;31(8):775‐786.
- Jooste V, Grosclaude P, Remontet L, Launoy G, Baldi I, Molinie F, Arveux P, Bossard N, Bouvier AM, Colonna M. Unbiased estimates of long‐term net survival of solid cancers in france. International journal of cancer. 2012.
- Roche L, Danieli C, Belot A, Grosclaude P, Bouvier AM, Velten M, Iwaz J, Remontet L, Bossard N. Cancer net survival on registry data: Use of the new unbiased Pohar‐Perme estimator and magnitude of the bias with the classical methods. International journal of cancer. 2012.
5
Biography CAILLIOT Christian Gender: Male Title: Director of Research Email: [email protected] Christian Cailliot is Director of Research at Unicancer. He joined Unicancer as leader of the R&D Unicancer team in 2011. Prior to Unicancer, he was responsible for early phase clinical studies at the French National Cancer Institute (Institut National du Cancer, INCa), which he had joined in 2008. In this position, he notably participated in the establishment of the INCa‐certified sites for early development (CLIP: Centres Labellisés de Phase Précoce). During this time he continued to work as a consultant for major pharmaceutical companies in hematology and oncology. In 1990, Christian created the French affiliate of Amgen. Amgen is one of the worldwide leading companies in biotechnology and oncology/hematology today. He successively held the positions of Medical Director and Director of Medical Affairs and Scientific Partnerships. He started his industry career at Roussel (today part of Sanofi) as Project Leader and later as Associate Medical Director. Christian Cailliot attended Necker Hospital Medical School (Paris). In addition he graduated from the “Ecole Supérieure de Commerce de Paris” in pharmaceutical marketing. Christian Cailliot published in many scientific journals, was teacher in a biotechnology master program and participates as expert in various organizations in the fields of Biotechnology, Hematology and Oncology. He is also a member of the American Society of Hematology and the French Society for Bone Marrow Graft and Cellular Therapy (Société Française de Greffe de Moëlle et de Thérapie Cellulaire (SFGM‐TC).
6
Biography CAUX Christophe Gender: Male Email: [email protected] Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM U1052/CNRS UMR5286/UMR S1052, Centre Léon Bérard Research Interests: Anti‐tumor immunity, Dendritic cells, Regulatory T cells, Chemokines, Toll‐Like Receptors Education: 1999 HDR, “Capacity to direct Research Programs within French Universities”, Université Claude Bernard,
Lyon 1989‐1991 Doctorat ès Sciences‐ Immunology, Université Claude Bernard, Lyon 1987 Ingénieur en Génie Biologique, Université Clermont Ferrand II 1987 DEA Cellular and molecular Biology, Université Clermont Ferrand II, 1986 Maîtrise de Génie Biologique, Université Clermont Ferrand II 1984 DUT (Diplôme Universitaire de Technologie) de Biologie Appliquée La Rochelle Professional Experience: 2011 Team from LabexDEVweCAN directed by Patrick Mehlen, and Lyric directed by Jean‐Yves Blay 2011 Co‐direction with Jean‐Yves Blay team N°11 “Therapeutic targeting of tumor cells and of their
immune environment”, CRCL, INSERM U1052 2010 Co‐direction “Platform of Innovation in Immunomonitoring and Immunotherapy” Centre Léon
Bérard 2006 DR2 INSERM 2004‐2010 Co‐direction with Jean‐Yves Blay team “Cytokine and Cancer” within the INSERM U590 2002‐2004 Head of Cellular and Molecular Biology department at Laboratory for Immunological
Research (LIR), Schering‐Plough, Dardilly, Dr G. Trinchieri 1999‐ 2002 Senior Scientist at Schering Plough, “anti‐tumoral immunity” Drs F. Cuss 1992‐1998 Junior Scientist at Schering Plough, “Dendritic cells (DC)” Dr J. Banchereau 1989‐1991 PhD “TNF and hematopoiesis” Schering‐Plough, Dr J. Banchereau Research or clinical achievements: Christophe Caux received his PhD degree from Université Claude Bernard from Lyon, France, and develops his scientific carrier since 1992 within the Laboratory for Immunological Research of Schering‐Plough in Dardilly, France. He has been involved in several scientific observations on human dendritic cells (DC), sentinel of the immune system: i) in vitro DC expansion, ii) DC heterogeneity, iii) DC/T/B lymphocyte dialogue, iv) chemokines in DC trafficking, v) Toll‐Like‐Receptors (TLR) in linking DC at the interface between innate and acquired immunity. These observations have been the basis for the definition of strategies to manipulate DC in vivo in order to reactivate anti‐tumor immunity. Since 2004 Dr Christophe Caux is Research Director within the INSERM unit “Oncogenesis and Tumor Progression” hosted in the Léon Bérard Cancer Center in Lyon, France. He is co‐directing with Pr. Jean‐Yves Blay, medical oncologist, the team “Cytokine and Cancer” that has a long history in tumor immunity. The team has in particular reported that in breast carcinoma the tumor environment impairs immune responses through alteration of DC development and functions. Their research interests focus on the biology of breast carcinoma and sarcoma with the objective to identify the mechanisms involved in immune subversion by cancer cells and to develop therapeutic strategies based on the immunogenicity of tumor cell death. Last 10 Publications: >100 publications in peer reviewed journals (Pubmed) since 1987. H‐index is 53, average citation 142 and sum of times cited 14241
7
- Faget J, Bendriss‐Vermare N, Gobert M, Durand I, Olive D, Biota C, Bachelot T, Treilleux I, Goddard‐Leon S, Lavergne E, Chabaud S, Blay JY, Caux C, Menetrier‐Caux C. ICOS‐ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.Cancer Res. 2012 Oct 1. [Epub ahead of print]
- Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, Renaudineau S, Poyet G, Labidi‐Galy SI, Goddard‐Leon S, Durand I, Le Mercier I, Bajard A, Bachelot T, Puisieux A, Puisieux I, Blay JY, Ménétrier‐Caux C, Caux C, Bendriss‐Vermare N. Impaired IFN‐α Production by Plasmacytoid Dendritic Cells Favors Regulatory T‐cell Expansion That May Contribute to Breast Cancer Progression.Cancer Res. 2012 Oct 15;72(20):5188‐97.
- Caux C. and Zitvogel L. Recent successes of cancer immunotherapy: a new dimension in personalized medicine? Targeted Oncol. 7:1‐2, 2012.
- Manuel M, Tredan O, Bachelot T, Clapissson G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret JF, Perol D, Chabaud S, Ray‐Coquard I, Labidi‐Galy I, Heudel P, Pierga JY, Caux C, Blay JY and Ménétrier‐Caux C. Lymphopenia Combined with low TCR Diversity (divpenia) predicts poor Overall Survival in Metastatic Breast Cancer Patient. OncoImmunology, 1(4):433‐42, 2012.
- Cassier PA, Treilleux I, Bachelot T, Ray‐Coquard I, Bendriss‐Vermare N, Menetrier‐Caux C, Tredan O, Goddard‐Leon S, Pin JJ, Mignotte H, Barthelemy‐Dubois C, Caux C, Lebecque S, Blay JY. Prognostic value of the expression of C‐Chemokine Receptor 6 and 7 and their ligands in non‐metastatic breast cancer. BMC Cancer.11:213‐23, 2011.
- Labidi‐Galy SI, Ray‐Coquard I, Sisirak V, Treilleux I, Meeus P, Mithieux F, Bajard A, Combes JD, Gobert M, Faget J, Guastalla JP, Tredan O, Ménétrier‐Caux C, Caux C, Blay JY and Bendriss‐VermareN.Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res. 171:5423‐34, 2011.
- Sisirak V, Vey N, Vanbervliet B, Duhen T, Puisieux I, Homey B, Bowman EP, Trinchieri G, Dubois B, Kaiserlian D, Lira SA, Puisieux A, Blay JY, Caux C, and Bendriss‐Vermare N. CCR6/CCR10‐mediated plasmacytoid dendritic cells recruitment to inflamed epithelia following instruction in lymphoid organs. Blood. 118(19):5130‐40, 2011.
- Hirsch I, Caux C, Hasan U, Bendriss‐Vermare N, Olive D. Impaired TLR7 and TLR9 signaling: from chronic viral infections to cancer. Trends Imumnol, 31(10):391‐7, 2010.
- Perrot I, Garrone P, Deauvieau F, Massacrier C, Brière F, Morel Y, Paturel C, Caux C. TLR3 on mDC and RIG‐I on NK cells engagement by dsRNA are required for optimal innate immune cell activation. J. Immunol. 185(4):2080‐8, 2010
- Gobert M, Treilleux I, Bendriss‐Vermare N, Bachelot T, Goddard‐Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D, Perez S, Pasqual N, Faure C, Ray‐Coquard I, Puisieux A, Caux C, Blay JY and Menetrier‐Caux C. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res., 69: 2000‐9, 2009.
8
Biography GAO Wei Qiang Gender: Male Title: Chair Professor Email: [email protected] Research Interests: - Stem cells and tissue repair/regeneration - Cancer stem cells and tumorigenesis - Hearing loss and inner ear hair cell regeneration Education: 1983.8‐1989.8: Ph.D. in Neurobiology at Columbia University, New York 1978.2‐1982.1: B.S. in Biology at Nanjing University, Nanjing, China Research or clinical achievements: In 1980’s‐1990’s, when I was a Ph.D. student and Post‐doc fellow at Columbia University and Rockefeller University, I made great contributions to the understanding of mechanisms of neuronal differentiation, particularly the cerebellar granule cell differentiation. After I established my own independent lab, I was the first to demonstrate that overexpression of a specific transcription factor Math1 is sufficient to induced inner ear hair cell production in postnatal rat cochleae, which changed the classic view that mammalian inner ear hair cells cannot be regenerated. More recently, my group published a paper in Nature showing that a single adult stem cell can generate a functional prostate. This study has important implication for tissue repair and identification prostate cancer stem cells. Five Selected Papers:
- Leong, KG, Wang, BE, Johnson, L and W‐Q Gao (2008) Generation of a prostate from a single adult stem cell. Nature, 456: 804‐808 (*Corresponding author).
- Shou, J, R. Soriano, S.H., Hayward, G.R. Cunha, P.M. Williams and W.‐Q. Gao (2002). Gene profiling of a human prostate tumor cell line model reveals a direct involvement of interferon signaling in prostate tumor progression. PNAS (USA), 99: 2830‐2835. (*Corresponding author).
- Zheng, J.L and W.‐Q. Gao (2000). Overexpression of Math1 induces robust production of extra hair cells in postnatal rat inner ears. Nature Neurosci. 3: 580‐586 (*Corresponding author).
- Gao, W.‐Q., X.‐L. Liu, and M.E. Hatten (1992). The weaver gene encodes a non‐autonomous signal for CNS neuronal differentiation. Cell 68: 841‐854.
- Gao, W.‐Q. and M.E. Hatten (1993) Neuronal differentiation rescued by implantation of weaver granule cell precursors into wild‐type cerebellar cortex. Science, 260: 367‐369.
9
Biography LU Qi Gender: Male Email: [email protected] – [email protected] Education: 2001.9‐2005.6: Bachelor Degree School of Public Health Shanghai Second Medical University (Now called Shanghai
Jiaotong University School of Medicine) 2010.1‐Present MPH, School of Public Health, Shanghai Fudan University Position: - Ethics Committee of Shanghai Renji Hospital—Secretary - Shanghai Association of Medical Ethics—Vice Secretary General - Medical Research Ethics Society of Shanghai Medical Association—Member and Secretary - Western Institutional Review Board in U.S. International Board —Member - Leadership Committee of MIFA (Middleton International Fellow’s Association in U.S.)—Member - WHO/SIDCER (Strategic Initiative for Developing Capacity in Ethical Review) recognition program —
Surveyor - FERCAP (Forum for Ethical Review Committees in Asia and the Western Pacific) —Member - Ethical Review Board of World Federation of Chinese Medicine Societies —Member Papers: - LU Qi, the experience of SIDCER recognition program, Chinese Medical Ethics, Volume 1, 2009 - LU Qi, the brief introduction of how to be a chairman of the EC, Chinese Medical Ethics, Volume 2, 2009 - CHEN Pei, LU Qi, XU Shan‐hua, Ethical Management—Soul of Hospital Management in the 21th
Century, Chinese Medical Ethics, Volume 4, 2010 - CHEN Pei, WANG Yu, LU Qi, the management of Hospital Ethics‐from new drug studies to the clinical
ethics, Chinese Medical Ethics, Volume 1, 2009
10
Biography MAGUER‐SATTA Véronique Gender: Female Email: veronique.maguer‐[email protected] Cancer Research Center of Lyon –CRCL, Inserm U1052, CNRS UMR 54286, Léon Bérard Cancer Center (CLB) Education: - HDR (Habilitation à diriger les recherches, Ancienne thèse d’Etat): Déc. 2006, Université de Lyon, Fr - Docteur de 3ème Cycle de Biologie: 10‐1994, Université de Lyon, Fr. Mention très Honorable, félicitation
du jury. (Rapporteur de thèse Pr Françoise BARRE‐SINOUSSI, Medical Nobel Prize 2008) Permanent Formation: 09‐2008 to 06‐2008: Management, CNRS, Lyon, France 06‐2000: Initiation à la salle blanche (Certi.i). Centre Léon Bérard, Lyon 11‐2000: Formation Azote (Air liquide santé). Centre Léon Bérard, Lyon 01‐1995: Radionucleotide safety and methodology. University of British Columbia,
Vancouver, Canada Research positions: April 2011: Director of research CNRS promotion (competitive exam) (DR2 CNRS section23) Since 2002: CNRS researcher (governmental lifetime position, CR1). Research in Pr Alain Puisieux U590,
CLB, Lyon, France. Research work: Stem cell, microenvironment and cancer Post doctoral positions: 1998‐2002: Post‐doctoral fellow in Pr JP Magaud U453, CLB, Lyon, France. Research work: Role of
FLRG protein in hematopoiesis. 1997: Post‐doctoral fellow in Pr Josy Reiffers Laboratory, Bordeaux, France. Research work: Role
of BCR‐ABL fusion gene expression apoptosis in CML (Chronic myeloid lekemia) primitive cells.
1994‐1996: Post‐doctoral fellow in Dr Connie Eaves Laboratory at the Terry Fox Laboratory, Vancouver, Canada. Research work: Role of BCR‐ABL fusion gene expression on the regulation of other genes expression involved in cell growth arrest and apoptosis in CML (Chronic Myeloid Leukemia) primitive cells. Regulation of human hematopoietic stem cell fate.
1991‐1994: PhD in Biological Sciences. Université Claude Bernard Lyon I. Laboratoire d’Immuno‐Virologie Moléculaire et Cellulaire, Faculté de Médecine Alexis Carrel. Research work: Study of proliferation and maturation of human thymocytes infected with HTLV‐I (Human T‐cell leukemia Virus type I). Implication of these cells in leukemogenesis.
Research Main Interest: My research activity started in 1990 in the Immuno‐Virology laboratory (Dr Gazzolo, Lyon, France), where I acquired cell culture, immunology and virology techniques. In 1994, I joined for 25 months Dr C. Eaves laboratory in Vancouver, Canada for a postdoctoral position to learn normal and leukemic hematopoiesis. I completed this training by a one‐year postdoctoral position (Pr Reiffers Bordeaux, France) to become familiar with a clinical approach of research in hematopoieisis. In 1998, in order to develop a research group on human hematopoiesis I joined the team of Dr Rimokh, Inserm U453 (Pr Magaud) on the site of the anti cancer center “Centre Leon Bérard”. After setting the hematopoietic techniques, I analyzed the function of a new protein “FLRG” during human hematopoiesis. In 2002, the CNRS recruited me as a permanent researcher (CR1). After finishing the projects on FLRG, I joined (01‐2004) the team “resistance and chromosomic instability” of Pr Dumontet (same Inserm Unit formerly U590, Pr Puisieux). This change results from my wish to focus my research on leukemic transformation of hematopoietic stem cells by developing new technical and conceptual aspect. Our research group is integrated since 2011 to the team 11 of the CRCL co‐directed by Dr Caux and Pr Blay. In 2011 I succeed to the research director recruitment (DR2 CNRS). Since 01‐2006, the research team that I drive is progressively becoming independent. Our
11
activities stayed focus on stem cells field but enlarged to different adult stem cells originated from various tissues in addition to hematopoietic stem cells. Indeed, by using three different systems, the main question the group is challenging to answer is to understand the relationship between, stem cells, microenvironment and cancer. In the hematopoietic context, we study the regulation of normal and leukemic hematopoiesis by analyzing the effects of cancer drugs on stem cell mobility, interactions with their environment. We explore the impact of all theses interactions on the drug resistance mechanisms of stem cells (models of CML and AML). We are developing stem cell model from human adult breast tissues in order to study the role of the microenvironment during oncogenesis and drug resistance. We study interactions between the adipose tissue with human mammary stem cells to study their involvement in drug resistance and relapse in Breast Cancer. We also more recently investigate the role of mechanical constraint on cancer stem cells phenotype, emergence and resistance. We are convinced that, even if technically very challenging, asking these questions in diverse systems should give us a strong insight (or at least the right tools to get to it) in general mechanisms of cancer stem cell regulation by their environment. In particular, it might help us to understand its involvement in oncogenesis and in process of drug resistance establishment, likely involved in relapse. This constitutes one of the major clinical issues of the next decade. Teaching: 2011 To‐date: EPHE‐2h. Stem cells and Cancer. Université Lyon I 2006 To‐date: Master 1‐2h. Stem cells and Cancer. Université Lyon I 2010: DESC Hematology (Clermont Ferrand). CML Stem Cells 10/11‐2006: Biotechnology specialization (ESSEP‐BIO). Université Catholique de Lyon 11‐2006: Master 1, 2h. Stem Cells and Cancer. Université Lyon I 10/11‐2003: Biotechnology specialization (ESSEP‐BIO). Université Catholique de Lyon
Biotechnology specialization (BIOTECH) Bac + 3. Université Catholique de Lyon, Lyon 10/11‐2002: DU R&D Biotech. Bac + 5. Université Paris VI, Jussieu 10/11‐2002: ESSEP‐BIO et BIOTECH 11‐2001 Adult formation (BIOFORMATION). Hematopoiesis and
CD34. Protocole ISAGE. Université Catholique de Lyon 10/11‐2001: ESSEP‐BIO. Bac + 5. Université Catholique de Lyon 01‐2001: BIOTECH Bac + 3. Université Catholique de Lyon 11‐1997: DEA Biologie Santé. Université Bordeaux 2. 2h. Apoptosis and role in hematopoiesis
regulation Society Member: Club d’Hematologie et d’Oncogenèse (CHO): office member 2012‐ 2016; French society of Immunology (SFI) since 1991.International Society of Hematology and Stem Cell (ISEH) Since 1995.International Society for Stem Cell research (ISSCR). Since 2008 (Active member), French society of Hematology (SFH) 2012‐to date Collaborations: French: - Pr BERGER Marc, EA3846 Groupe Hématologie Clermont Ferrand Université d’Auvergne/CHU - Dr PASQUET Jean‐Max, Laboratoire Hématopoïèse Leucémique et Cible Thérapeutique, U1035,
Bordeaux - Dr ARGOUL Françoise Equipe Mechano‐genetics of the cell, USR3010 – LJC CNRS Lyon - Dr AUBERGER Patrick, U895, Cell death differentiation and cancer, Faculté de médecine, Nice International: - Pr GAO Wei‐Qiang Associate Dean, Med‐X Research Institute Director, Renji Hospital Stem Cell
Research Center KC Wong Chair Professor, 1945 Hua Shan Road, Shanghai 200030 China - Pr ZANDSTRA Peter, Institute of Biomaterials and Biomedical Engineering, University of Toronto,
Canada
12
Biography PENAULT‐LLORCA Frédérique Gender: Female Title: Professor Département d'Anatomie et de Cytologie Pathologiques. Centre Jean Perrin, Clermont‐Ferrand E‐mail : [email protected] Education: October 1992: Pathology Degree March 1993: MD Subject HER2 expression in breast cancer and quality control June 1995‐ D.E.S.C. oncology July 1996‐ PhD in Molecular and Cellular Biology
Université d’Aix‐Marseille II. Mention très honorable “FGF and FGFR family in breast cancer” December 1999 “Habilitation à diriger les recherches” Université d’Auvergne “Translational research in breast cancer” September 2000 Maître de conférence des universités/praticien hospitalier (Associate Professor) Since September 2003 Professor of pathology Since September 2007 “First class” Professor of pathology Position: - Professor of pathology, Head of the Department of pathology and tumor biology / Centre Jean Perrin,
Clermont‐Ferrand - Scientific Director, Centre Jean Perrin - Director of the Research Unit ERTICa (University of Auvergne) Main Subjects of Interest: - Breast pathology: DCIS, Bilateral breast cancer, response to treatment, neo adjuvant therapy - Ovarian pathology: grading, familial ovarian carcinomas (member of the European consortium) - Endometrial pathology and Tamoxifen therapy - Tyrosine kinase receptors (HER2, EGFR) and other therapeutic targets (angiogenesis, c‐kit ….)
immunohistochemistry and molecular Biology - Pathologist coordinator of clinical trials from the Federation des “Centres de Lutte contre le Cancer” - Active member of the French quality control group (AFAQAP) (Head of immunohistochemistry and
molecular biology tests) - Member of the breast cancer research group in pathology (GEFPICS) - Member of ESMO, ASCO, AACR, ESP - Education in Oncology, molecular biology and cancer pathology (general and special) at the medical
school (University of Clermont‐Ferrand) Selected Peer Reviewed Publications: - Romero P., Dauplat M.M., Mishellany F., Gimbergues P., Le Bouedec G., Penault‐Llorca F. ‐ Chirurgie
conservatrice du cancer du sein : évaluation des berges d'exérèse lors de la chirurgie première; Oncologie 2010; 12: 1‐5
- Beau‐Faller M., Blons H., Mauguen A., Pretet J.L., Piard F., Degeorges A., Penault‐Llorca F., De Cremoux P., Bringuier P.P., Olschwang S., Solassol J., Lacroix L., Lizard S., Zalcman G., Richard N., Escande F., Nanni I., Rouquette I., Boyer J.C., Bieche I., De Fraipont F., Denis M., Mosser J., Pignon J.P., Morin F., Cadranel J. ‐ Various sensitive molecular detection techniques for EGFR mutations in NSCLC, by 20 French Centers ‐ Preliminary results on cell lines of cell lines of ERMETIC‐2/PREDICT.AMM studies; J Thorac Oncol 2011 ; 6, 6 (suppl S): 1070‐1071
13
- Gligorov J., Arsovski O., Belkacemi Y., Bachouchi M., Penault‐Llorca F., Chauvet M.P., Senel‐Bese N., Valli M.C., Boussen H., Al Halabi A., Bensalem A., Hery M., Sallaku A., Villa S., Ychou M., Azria D., Boualga K., Bouaouina N., Cals L., Cohen Y., Geara F., Vasev N., Nasrallah H., Ozsahin M., Benider A., Kerrou K., Koroveshi D., Kuten A., Muto P., Thabet K., Todorovic V., Bouzid K., Bashar V., Carrato A., Filipovic M., Gridelli C., Mandel, M. N., Tsoutsou P.A. G., Zouhair A., Belkacemi Y., Bar Hana M., (Bernstein Z., De Sabata S., Hamdicherif M., Lokiec F., Mahjoubi M., Marsiiglia H., Mahi Y., Gligorov J., Tsoutsou, Kuten A. P. G., Boussen H., Geara F., Bese N., Group Author(S): Arome ‐ Guidelines, minimal requirements and standard of cancer care around the Mediterranean Area: report from the Collaborative AROME (Association of Radiotherapy and Oncology of the Mediterranean Area) working parties AROME; Crit Rev Oncol Hematol 2011; 78: 1‐16
- Jacquemier J., Boher J.M., Roche H., Esterni B., Serin D., Kerbrat P., Andre F., Finetti P., Charafe‐Jauffret E., Martin A.L., Campone M., Viens P., Birnbaum D., Penault‐Llorca F., Bertucci F. ‐ Protein expression, survival and docetaxel benefit in node‐positive breast cancer treated with adjuvant chemotherapy in the FNCLCC ‐ PACS 01 randomized trial; Breast Cancer Res 2011; 13, 6
- Penault‐Llorca F., Chenard M.P., Bouche O., Emile J.F., Bibeau F., Metges J.P., Andre T., Monges G. ‐ HER2 et cancer gastrique. Recommandations pour la pratique clinique en 2011; Ann Pathol 2011; 31: 78‐87
- Penault‐Llorca F., Coeffic D., Delozier T., Dohollou N., Freyer G., Gligorov J., Hardy‐Bessard A.C., Jacot W., Misset J.L., Nabholtz J.M., Petit T., Spielmann M., Namer M. ‐ Le cancer du sein sans envahissement ganglionnaire. Au‐delà des consensus internationaux : une approche pragmatique; Bull Cancer 2011; 98: 807‐825
- Chene G., Raoelfils I., Cayre A., Dauplat J., Bignon Y.J., Jaffeux P., Aublet‐Cuvelier B., Penault‐Llorca F. ‐ N'oubliez pas les trompes ! Etude morphologique et immunohistochimique des trompes à risque génétique (mutation BRCA); Gynecol Obstet Fertil 2012; 40: 14‐18
- Arnould L., Roger P., Macgrogan G., Chenard M.P., Balaton A., Beauclair S., Penault‐Llorca F. ‐ Accuracy of HER2 status determination on breast core‐needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH) (epub ahead of print); Mod Pathol 2012
Selected Book Chapters: - Penault‐Llorca F. ‐ Editeur scientifique ‐ Le cancer du sein. Eds.: Morère J.F., Penault‐Llorca F., Aapro
M.S., Salmon R. Editions Springer, Paris (France), 2007, 313 pages. - Penault‐Llorca F. ‐ Molecular and biological diagnosis of early gynecologic cancers. In: Early pathologic
diagnosis of gynecologic cancer. Including a clinician's view. Eds.: Deligdisch L., Altchek A. World Scientific Publishers, 2008, 312 pages.
- Penault‐Llorca F., EL FATEMI H., MISHELLANY F. ‐ Rhabdomyosarcoma of the vagina and cervix. In: Pediatric, adolescent and young adult gynecology. Eds.:Altchek A., Deligdisch L. Blackwell Publishing, 2009, 520 pages, chapter 51.
- Penault‐Llorca F., RIVERA‐SERRANO E., ESSAMET W. ‐ Benign ovarian disorders. In: Pediatric, adolescent and young adult gynecology. Eds.:Altchek A., Deligdisch L. Blackwell Publishing, 2009, 520 pages, chapter 52.
- Penault‐Llorca F.‐ Famille HER, le bon, la brute et le truand. In: Les cibles membranaires de la cellule tumorale. Ed.: Blay J.Y. John Libbey, 2009, 96 p.
14
Biography PHILIP Thierry Gender: Male Title: General Councillor Email: [email protected] 1978: Certified in Human Biology 1980: Qualified in Pediatrics 1981‐1983: Assistant Professor of Medicine, Lyon University 1981: Diploma of Education and Research in Human Biology (DERBH) 1985‐1987: Head, Medical Unit, Day Hospital, Centre Léon Bérard 1987‐1989: Head, Bone Marrow Transplant Unit (clinics and laboratory), Centre Léon Bérard 1988 ‐: University Professor in Medical Oncology 1989‐2009: Director, Centre Léon Bérard (Léon‐Bérard Comprehensive Cancer Center, Lyon, France),
President, Fédération Nationale des Centres de Lutte Contre le Cancer (French Federation Comprehensive Cancer Centers), 1997‐2002
1996‐2000: Head, Pediatrics Unit, Centre Léon Bérard (Léon Bérard Comprehensive Cancer Center), Lyon, France
2004‐2010: Vice‐President Regional Assembly (Rhône‐Alpes Region), in charge of Health and Sport‐
oriented activities 2007: Head of Scientific Governance of SOR 2008‐: President, Agence Nationale d’Education par le Sport 2008‐: Mayor, 3rd District of Lyon 2010‐2011: President, Special advisor in charge of University research innovation and Social sanitary
formation (Rhône‐Alpes Region)
15
Biography PRÉAU Marie Gender: Female Title: Professor of Social Health Psychology Email: marie.preau@univ‐lyon2.fr Research Group in Social Psychology (GRePS), Lyon 2 University Education: 2001‐2004: PhD, Social Health Psychology, Provence University, Marseille 2004‐2006: Postdoctoral fellow, French National Health and Research Institute, Marseille 2006‐2011: Associate professor, Nantes University Since 2011: Professor, Lyon 2 University Scientific activities: - Research Associate, U912, French National Health and Research Institute, Marseille since 2001 - Member of the Committee for Disease Prevention, Health Promotion and Education, High Council for
Public Health, Ministry of Health since 2011 - Scientific supervisor, social sciences and humanities, epidemiology, public health department, CLARA
since 2012 - Member of evaluation department (CSS), French National Health and Research Institute (INSERM) - President of the Francophone Association of Health Psychology (AFPSA) - Member of Coordinated Action (group 18), National Agency for AIDS Research Research Interest - Quality of life among chronic illness patients, psychosocial challenges in the context of chronic illness:
patient‐provider relationship, social relationships, health discrimination, adherence behaviors, social support
- Prevention programs, sexual risk behavior for HIV infection and other chronic illness - Community based research: methodology and ethics implication Five selected papers: - Préau, M.,Bouhnik, A.D., Le Corroller‐Soriano, A.G. (in press). Two years after a cancer diagnosis,
relationship between health related quality of life, coping strategies and spirituality, Psychology, Health and Medicine.
- Préau, M., Protopopescu, C., Raffi, F., Rey, D., Chene, G., Marcellin, F., Perronne, C., Ragnaud, J.M., Leport, C ;, Spire, B. (2012). Satisfaction with care in HIV‐infected patients treated with long term follow up antiretroviral therapy: the role of social vulnerability, Aids Care, 24(4), 434‐43.
- Préau, M.,Bouhnik, A.D., Rey, D., Mancini, J., Moatti, J.P. (2011). Two years after cancer diagnosis, which couples become closer. European Journal of Cancer Care, 20(3), 380‐388.
- Mancini, J., Rey, D., Préau, M., Le Corroller‐Soriano, A.G., Moatti, J.P. (2011). Barriers to procreational intentions among cancer survivors 2 years after diagnosis: a French national cross‐sectional survey. Psycho‐Oncology, 20(1), 12‐18.
- Préau, M., Leport, C., Villes, V., Michelet, C., Collin, F., Carrieri, M.P., Ragnaud, J.M., Taieb, A., Raffi, F., Spire, B. (2008). Break of trust in patient‐provider relationship in HIV infected patients started on a PI containing antiretroviral therapy. JAIDS, 47(4) 467‐471.
16
Biography PUISIEUX Alain Gender: Male Title: Professor Email: [email protected] Current Positions: - Director of the Cancer Research Center of Lyon (CRCL, INSERM U1052 ‐ UMR CNRS 5286) - Professor of Biochemistry – University Claude Bernard Lyon I Academic Titles: - Senior member of the Institut Universitaire de France - Member of the National Academy of Pharmacology (Académie Nationale de Pharmacie) - Member of the National Academy of Medicine (Académie Nationale de Médecine) - Professor of Biochemistry ‐ University Claude Bernard Lyon I - Habilitation à Diriger des Recherches (HDR) – University Claude Bernard Lyon I (1997) - State Doctorate in Sciences ‐ University René Descartes de Paris V (1993) - State Doctorate in Pharmacy ‐ Faculté de Paris XI (1989) Research Interests: - Role of the Epithelial‐Mesenchymal transitions in tumour development - Cellular plasticity and tumor heterogeneity - Escape from oncogene‐induced senescence and apoptosis Scientific Cursus: - Department of Immunology, Institut Gustave Roussy (1987‐1989). Pr Bellet - Molecular Hepatology Laboratory. Cancer Center. Massachusetts General Hospital of Boston. Harvard
Medical School, Boston. (1989‐1991). Pr J. Wands. Dr. M. Ozturk - Laboratory of Molecular Oncology. Centre Léon Bérard. Lyon. (1992‐1993). Dr. M. Ozturk Scientific Publications: - Author of 112 publications in international scientific journals and 41 in national scientific journals - More than 150 presentations at national and international conferences Five selected publications: - Valsesia‐Wittmann S, Magdeleine M, Dupasquier S, Garin E, Jallas AC, Combaret V, Krause A, Leissner P,
Puisieux A. Oncogenic cooperation between H‐Twist and N‐Myc overrides failsafe programs in cancer cells. Cancer Cell, 6: 625‐630, 2004 (FI: 26,63).
- Mehlen P, Puisieux A. Metastasis: a question of life or death. Nature Reviews Cancer, 6: 449‐458, 2006 (FI : 34,98).
- Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S, Maestro R, Voeltzel T, Selmi A, Valsesia‐Wittmann S, Caron de Fromentel C, Puisieux A. Induction of EMT by twist proteins as a collateral effect of tumor‐promoting inactivation of premature senescence. Cancer Cell, 14: 79‐89, 2008.(FI : 26,63).
- Janoueix‐Lerosey I, Lequin D, Brugières L, RibeiroA, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau‐Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature, 455:967‐971, 2008 (FI : 34,48).
- Doreau A, Belot A, Bastid J, Riche B, Trescol‐Biemont MC, Ranchin B, Fabien N, Cochat P, Pouteil‐Noble C, Trolliet P, Durieu I, Tebib J, Kassai B, Ansieau S, Puisieux A, Eliaou JF, Bonnefoy‐Bérard N. IL‐17 synergizes with BAFF to control B cell biology and impacts SLE pathophysiology. Nature Immunology, 10:778‐85, 2009 (FI: 25,33).
17
Biography QIN Wenxin Gender: Male Title: Professor, Principal Investigator (PI) Email: [email protected] Education: 2007‐2008: Leroy Hood Laboratory, Institute for Systems Biology, Seattle, USA. Visiting Scholar 1995‐1998: Shanghai Medical College, Fudan University, Shanghai, China. Ph. D. 1991‐1994: School of Medicine, Soochow University, Suzhou, China. M. Sc. 1981‐1985: College of Life Sciences, Wuhan University, Wuhan, China. B. Sc. Professional Experience: 2004‐present: Professor, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute,
Shanghai, China 2000‐2004: Associate Professor, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer
Institute, Shanghai, China 1998‐2000: Lecturer, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute,
Shanghai, China 1993‐1998: Lecturer, Laboratory of Brain Cancer, Soochow University, Suzhou, China 1985‐1993: Research Assistant, Laboratory of Brain Cancer, Soochow University, Suzhou, China Research or clinical achievements: Dr. Wenxin Qin is currently a professor and a senior principle investigator of the State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute. He graduated with a B.Sc in Life Sciences from Wuhan University in 1985 and received his Ph.D from Shanghai Medical School of Fudan University in 1998. Between 2007 and 2008, as a visiting scientist, he did collaboration research in Leroy Hood’s laboratory at Institute for Systems Biology, Seattle. Prof. Qin is head of Tumor Microenvironment in the Institute. His group is committed to exploring molecular mechanisms of the development and progression of cancer. Research interest of his lab is focused on: tumor microenvironment, cancer metastasis, and cancer biomarkers. In the field of tumor microenvironment and cancer metastasis, Prof. Qin’s group first reported that vacuolar H+‐ATPase (V‐ATPase), which regulates the pH of tumor microenvironment, could enhance the invasion and metastasis of hepatocellular carcinoma (HCC) (Cancer Research 2007, Cancer Research 2005). Subsequently, they revealed LASS2, a gene identified and cloned by Prof. Qin’s lab, suppressed the proliferation and metastasis of cancer by binding to V‐ATPase and inhibiting the functions of V‐ATPase (Oncogene 2012, Cancer Letters 2009). Using systems biology approach, Prof. Qin’s group is aiming to discover biomarkers for cancer diagnosis and prognosis and drug targets for cancer treatment. They found serum DKK1 (Dicckopf‐1) had satisfactory diagnostic and prognostic value for lung cancer (Clinical Chemistry 2009) and HCC (The Lancet Oncology 2012, Journal of Hepatology 2009). The patent “Use of DKK1 protein in the cancer diagnosis” has just been licensed by the United States Patent and Trademark Office. Selected Publications - QiujinShen, Jia Fan, Xin‐Rong Yang, Yexiong Tan, Weifeng Zhao, Yang Xu, Ning Wang, YongdongNiu,
Zheng Wu, Jian Zhou, Shuang‐JianQiu, Ying‐Hong Shi, Bin Yu, Ning Tang, Wei Chu, Min Wang, Jinhua Wu, Zhigang Zhang, Shengli Yang, JianrenGu, Hongyang Wang, Wenxin Qin#. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large‐scale, multicentre study. The Lancet Oncology 2012 Aug; 13(8):817‐26 (# corresponding author).
- Shaohua Fan, YongdongNiu, Ning Tan, Zheng Wu, Yanyan Wang, Haiyan You, RonghuKe, Jin Song, QiujinShen, Wenqiu Wang, Genfu Yao, HuiqunShu, Hechun Lin, Ming Yao, Zhigang Zhang, JianrenGu, Wenxin Qin#. LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor
18
microenvironment through inhibiting activity of V‐ATPase proton pump. Oncogene 2012 May 14. doi: 10.1038/onc.2012.183. [Epub ahead of print] (# corresponding author).
- Shi Le Sheng, Gang Huang#, Bin Yu, Wen Xin Qin#. Clinical significance and prognostic value of serum Dickkopf‐1 concentrations in patients with lung cancer. Clinical Chemistry 2009 Sep;55(9):1656‐64 (# corresponding author).
- Haiyan You, Jie Jin, HuiqunShu, Bin Yu, Angelo De Milito, Francesco Lozupone, Yun Deng, Ning Tang, Genfu Yao, Stefano Fais, JianrenGu, Wenxin Qin#. Small interfering RNA targeting the subunit ATP6L of proton pump V‐ATPase overcomes chemoresistance of breast cancer cells. Cancer Letters 2009 Jul 18;280(1):110‐9 (# corresponding author).
- Bin Yu, Xinrong Yang, Yang Xu, Genfu Yao, HuiqunShu, Biaoyang Lin, Leroy Hood, Hongyang Wang, Shengli Yang, JianrenGu, Jia Fan#, Wenxin Qin#. Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta‐catenin accumulation and poor prognosis in hepatocellular carcinomas. Journal of Hepatology 2009 May;50(5):948‐57 (# corresponding author).
- Jie Jin, Haiyan You, Bin Yu, Yun Deng, Ning Tang, Genfu Yao, HuiqunShu, Shengli Yang, Wenxin Qin#. Epigenetic inactivation of SLIT2 in human hepatocellular carcinomas. Biochemical and Biophysical Research Communications 2009 Jan 30;379(1):86‐91 (# corresponding author).
19
Biography SALLES Gilles Gender: Male Title: Professor Email: gilles.salles@chu‐lyon.fr Service d’Hématologie – Centre Hospitalier Lyon Sud Diplomas / Formation: 1989: MD Degree, Medicine, Claude Bernard University, Lyon, France 1996: PhD Degree, Immunology, Claude Bernard University, Lyon, France Professional Cursus: 1990 – present: Hospital Practitioner, South Lyon Hospital Center, Lyon‐Nord Faculty University
Lyon 1, France 1996: Assistant Professor, Claude Bernard University, Lyon, France 1984‐1989: Resident, Lyon University Hospital, France Five Major Publications: - Ribrag V, Koscielny S, Casasnovas O, Cazeneuve C, Brice P, Morschhauser F, Gabarre J, Stamatoullas A,
Lenoir G, Salles G. Pharmacogenetic study in Hodgkin’s lymphomas reveals the impact of UGT1A1 polymorphisms on patients’ prognosis. Blood. 2009, 113:3307‐13 (A)
- Ribrag V, Gisselbrecht C, Haioun C, Salles G, Golfier JB, Ertault M, Ferme C, Briere J, Brice P, Mounier N. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B‐cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer. 2009, 115:4540‐6 (A)
- Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, Delmer A, Bordessoulle D, Tilly H, Corront B, Allard C, Foussard C, Bosly A, Coiddier B, Gisselbrecht C, Solal‐Celigny P and Salles G. Long term follow‐up of 536 newly diagnosed follicular lymphoma patients in the pre‐rituximab era: Effect of pre‐treatment prognostic variables and response quality on survival. A study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Journal of Clinical Oncology, 2010, 28:822‐9. (A)
- Larouche J‐F, Berger F, Chassagne‐Clément C, French M, Callet‐Bauchu E, Sebban C, Ghesquières H, Broussais‐Guillaumot F, Salles G, Coiffier B. Lymphoma recurrence 8 years of later following diffuse large B‐Celle lymphoma : Clinical characteristics and outcome. Journal of Clinical Oncology, 2010 28(12):2094‐100. (A)
- Salles G, Seymour JF, Offner F, López‐Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial. Lancet 2011, 377:42‐51 (A).
20
Biography TRILLET‐LENOIR Véronique Gender: Female Title: Professor Email: veronique.trillet‐lenoir@chu‐lyon.fr Véronique Trillet‐Lenoir was born and trained in Lyon, France, where she obtained her MD in 1981 and her PhD in 1991. In 1986, she did a postdoctoral residency at the Medical Oncology Department of the MD Anderson Cancer Center in Houston, Texas. She was recruited in 1993 as a full professor of Cancerology in the Lyon I Claude Bernard University. Since 2003, she is Head of the Medical Oncology Department at the University Hospital of Lyon (Hospices Civils de Lyon), located in the South Lyon Hospital Center (Centre Hospitalier Lyon Sud). Her team is involved in the early evaluation of new anticancer molecules (phase I clinical trials), as part of a joint program between the French and the North American National Cancer Institutes. This clinical activity is closely linked to the research team named “Tumor Biology Modelisation and Anticancer Treatment Optimization”, which is part of the “Targeting Treatment in Oncology” research unit in the South Lyon Charles Mérieux University, a branch of the Lyon I Claude Bernard University. The Medical Oncology Department is also involved in clinical trials on tumor response evaluation, medico‐economics, pharmacology of anti‐neoplasic drugs and geriatric oncology. Veronique Trillet‐Lenoir directed the Coordination Center for Oncology of the University Hospital of Lyon between 2002 and 2007. From 2005 to 2007, she held the position of scientific advisor in the “Quality of Care and Access to Innovations” Department of the French National Cancer Institute, Paris. She is past President and General Secretary of the French National Cancerology Council, a national organization which represents all categories of medical practitioners in the field of cancer and interacts with health authorities in terms of improvement and evaluation of clinical practice. In the upcoming year, she will be President of the CLARA Regional Cancer Research Cluster’s Steering Committee.
21
Biography WANG Hong‐Xia Gender: Female Title: Attending Doctor Email: [email protected] Education: 2009.12~2010.2 Visiting Scholar
Memorial Sloan‐Kettering Cancer Center, New York, USA 2008.02~2009.2 Visiting Scholar
Dpt. of Molecular Pathology, Mount Sinai School of Medicine, New York, USA 2007.10~present Attending doctor, Dpt. of Oncology
Shanghai Renji hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, P.R. China
2007.09~2010 Shanghai Jiaotong University, School of Medicine, Shanghai, P.R. China ‐ Ph.D. in Oncology
2003.09~2006.7 Shanghai Jiaotong University, School of Medicine, Shanghai, P.R. China – M.S. in Oncology
1995.09~2000 Medical College of Suzhou University, Jiang Su Province, P.R. China ‐ B.S. in Clinical Medicine
Research or clinical achievements: 2011 Shanghai Pujiang Program, Shanghai 2011 Ten Best Young Award, Shanghai Renji Hospital 2008 Excellent Young Teacher Award, Shanghai Municipal Education Committee 2007 Excellent Young Teacher Award, Renji hospital of Shanghai Jiaotong, University, School of Medicine 2006 A Hundred People Plans, Shanghai Jiaotong University, School of Medicine
Papers: - Wang H, Huang M, Zhang DY, et al. Global Profiling of Signaling Networks: Study of Breast Cancer Stem
Cells and Potential Regulation. The oncologist. 2011; 16(7): 966‐979. (First author/Corresponding author)
- Wang HX, Zhang FC, Ye F, Ma Y, David YZ. The effect of coptischinensis on the signaling network in the squamous carcinoma cells. Front Biosci. 2011 Jan 1;3:326‐40. (First author)
- Ling W, Fan Jie, Yue M, Yuan M, Wang H. Capecitabine‐based chemotherapy for metastatic colorectal caner. J Cancer Res Clin Oncol.2010, oct 9. PMID: 20936301. (Corresponding author)
- Zhang DY, Ye F, Gao L, Liu X, Zhao X, Che Y, Wang HX, Wang L, Wu J, Song D, Liu W, Xu H, Jiang B, Zhang W, Wang J, Lee P. Proteomics, pathway array and signaling network‐based medicine in cancer. Cell Div. 2009 Oct 28;4:20.
- Hu J, Zhao G, Wang HX. A meta‐analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. Journal of hematology and oncology. 2011, Mar 26, 4:11. (Corresponding author)
- Zhang FC, Song SL, Ma Y, Tang L, Xu YC, Wang HX. Effect of Fibroblasts on Breast Cancer Cell Mammosphere Formation and the Regulation of Stem Cell‐Related Gene Expression. Int J Mol med.2011, Sep; 28(3): 365‐371. (Corresponding author)
- Wang HX, Gillis A, Zhao CY, et al. Crocidolite asbestos‐induced signal pathway dysregulation in mesothelial cells. Mutat Res. 2011 Aug 16; 723(2): 171‐176.(First author)
- Ma Y, Tang L, Wang HX, et al. Capecitabine for the treatment of advanced gastric cancer: efficacy, safety and ethnicity. J Clin Pharm Ther. 2011 Sep 26. doi: 10.1111/j.1365‐2710.2011.01289.x. (Corresponding author)
- Ma Y, Zhang Z, Tang L, Xu YC, Xie ZM, Gu XF, Wang HX. Cytokine‐Induced Killer (CIK) Cells In The Treatment Of Patients With Solid Carcinomas: A Systematic Review And Pooled Analysis. Cytotherapy.
22
2012 Apr;14(4):483‐93. (Corresponding author) - Xu YC, Wang HX, Tang L, et al. A systematic review of vinorelbine for the treatment of breast cancer.
The Breast Journal. 2011. (accepted) (Corresponding author) - Fang Ren, Ying‐Chun Xu, Hong‐Xia Wang, et al. Adjuvant chemotherapy, with or without postoperative
radiotherapy, for resectable advanced pancreatic adenocarcinoma: continue or stop? Pancreatology. 2012, Feb 29.(Corresponding author)
- Dai JQ, Wang HX, Shi YH, et al. Impact of bile acids on the growth of human cholangiocarcinoma via FXR. Journal of hematology and oncology. 2011, 4: 41.
- Ma Y, Xu YC, Tang L, et al. Cytokine‐induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Experimental Hematology & Oncology. 2012, 1:11. (Corresponding author)
- Yuan Ma, Wang HX. Investigation of signal pathways in breast cancer stem cell. Chinese Journal of Oncology. 2010, 32(12): 881‐885. (Corresponding author)
Grant support: H.X. Wang, PI - Leading Academic Discipline Project of Shanghai Municipal Education Committee, Project Number:
J50208 H.X. Wang, PI - National Natural Science Foundation of China. Project Number: 81102015 H.X. Wang, PI - Shanghai Pujiang Program. Project Number: 11PJ1406500 H.X. Wang, PI - Chinese Ministry of Civil Affairs - Evaluation of the effect and efficacy of XELOX and EOX in elderly gastric cancer patients H.X. Wang, PI - Shanghai Municipal Education Committee - Study of Cp‐Trail‐siPROM1 co‐expressed genes in colon cancer stem cells H.X. Wang, PI - Shanghai Science and Technology Commission. Project Number: 09ZR1417900 - Reconstruction of signaling network of Malignant mesothelioma
23
Biography WANG Ting Gender: Female Title: Associate Chief Fellow and Associate Professor Email: [email protected] Education: 1992 –1997 Nanjing Medical University, Nanjing, China
Medicine M.D 1997–2000 Southeast University School of Medicine, Nanjing, China
Hematology and Oncology M.A 2000–2003 Shanghai Second Medical University, Shanghai, China
Hematology and Oncology M.A 2006–2009 National Institutes of Health, Bethesda, USA
Cancer Metabolomics and Nuclear Receptors Postdoctoral training Positions and Employment 7/2003 – 11/2004 Internal Medicine Residency, Department of Hematology, Shanghai Renji Hospital,
Shanghai Jiao Tong University School of Medicine, Shanghai, China 11/2004 – 2/2006 Medical Oncology and Hematology Fellowship, Department of Hematology,
Shanghai Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2/2006 – 12/2009 Postdoctoral fellow, Lab of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, U.S.
12/2009 – present Associate Chief fellow and Associate Professor, Department of Hematology, Shanghai Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Research or clinical achievements: 2007 Young Scientist Award, the American Society for Pharmacology and Experimental Therapeutics, USA 2007 Fellows Award for Research Excellence, National Institutes of Health, U.S. 2009 Fellows Award for Research Excellence, National Institutes of Health, U.S. 2009 Second prize of Chinese Medical Science and Technology, Chinese Medical Association, China 2010 Shanghai Pu Jiang Scholar, Shanghai Science and Technology Commission, Shanghai, China 2010 Mentor Award, Shanghai Jiao Tong University School of Medicine, Shanghai, China 2011 Mentor Award, Shanghai Municipal Education Commission, Shanghai, China 2012 Hundred Talents Program, Shanghai Jiao Tong University School of Medicine, Shanghai, China Research Grants - Fund supported by National Natural Science Foundation of China (NSFC), Principal Investigator
“Role of glycolysis in the pathogenesis of lymphoma and the intervention study”, (Grant 81172253), 1/2012 – 12/2015
- Pu Jiang Scholar Program supported by Shanghai Science and Technology Commission, Principal Investigator “Screening for biomarkers of Non‐Hodgkin’s lymphoma”, (Grant 10PJ1407100), 7/2010 – 6/2012
- Young Scientists Fund supported by National Natural Science Foundation of China (NSFC), Principal
Investigator “Role of inherence and drug environmental factors in the development of CYP3A5 multidrug resistance mechanism of leukemia and reversing study” (Grant 30400183), 1/2005 – 12/2007
Peer‐Reviewed Original Research Articles: - Wang T, Shah YM, Matusbara T, Zhen Y, Tanabe T, Nagano T, Fotso S, Krausz KW, Zabriskie TM, Idle JR,
24
and Gonzalez FJ. Control of steroid 21‐oic acid synthesis by peroxisome prolferator‐activated receptor alpha and the role of the hypothalamic‐pituitary‐adrenal axis. J Biol Chem. 285(10): 7670‐7685, 2010. PMID: 20032461
- Wang T, Ma X, Krausz KW, Idle JR, and Gonzalez FJ. Role of pregnane X receptor in control of all‐trans retinoic acid (ATRA) metabolism and its potential contribution to ATRA resistance. J PharmacolExpTher. 324(2): 674‐684, 2008. PMID: 17962516
- Zhong H, Wang HR, Yang S, Zhong JH, Wang T, Wang C, and Chen FY. Targeting Smad4 links microRNA‐146a to the TGF‐beta pathway during retinoid acid induction in acute promyelocytic leukemia cell line. Int J Hematol. 92(1): 129‐35, 2010. PMID: 20577838
- Ma X, Shah YM, Guo GL, Wang T, Krausz KW, Idle JR, and Gonzalez FJ. Rifaximin is a gut‐specific human pregnane X receptor activator. J PharmacolExpTher. 322(1): 391‐398, 2007. PMID: 17442842
- Ma X, Cheung C, Krausz KW, Shah YM, Wang T, Idle JR, and Gonzalez FJ. A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug MetabDispos. 36(12): 2506‐2512, 2008. PMID: 18799805
- Shen LJ, Chen FY, Wang T, Wang HR, Zhong JH, Han JY, Ouyang RR. Polymorphisms of CYP3A5 gene in acute leukemia patients and their role in chemotherapy and prognosis. Zhongguo Shi Yan Xue Ye XueZaZhi. 16(1): 26‐30, 2008. PMID: 18315894
- Wang T, Chen FY, Han JY, Zhong JH, Teng Y, Ouyang RR. The relationship between cytochrome P450, subfamily IIIA, polypeptide 5 gene and drug resistance in leukemia cell lines. ZhonghuaNeiKeZaZhi. 43(7): 527‐9, 2007. PMID: 15312409
- Wang T. Role of glycolysis in the pathogenesis of Non‐Hodgkin lymphoma. Haematologica. 2011. Book Chapters Wang T. Chapter 31 “Production of Erythrocytes”, Chapter 65 “Neutropenia and Neutrophilia”, and Chapter 94 “Chronic Lymphocytic Leukemia and Related Diseases” In CHEN Zhu & CHEN Saijuan’s, The Chinese translation edition of Williams Hematology (Eighth Edition), McGraw‐Hill Education (Asia) and People’s Medical Publishing House, 1st Edition, 2011, pp 408‐419, 869‐880, 1330‐1376. ISBN 978‐7‐117‐14824‐5 Plan for the future cooperation: We hope to establish relations of cooperation in clinical technology in the field of off‐pump coronary artery bypass surgery, diseases of the thoracic aorta, minimally invasive valve surgery. We also with pleasure enhance the level of scientific research such as in the field of stem cells, perfusion and restenosis after CABG.
Board Certifications - 2003: Chinese Board of Internal Medicine Committee Activities - Shanghai Pharmaceutical Association (SPA), Antibiotics Committee: Member, 2011 – present Professional Memberships - American Association for Cancer Research (AACR): Member, 2007 – present - Chinese Medical Association Shanghai Branch, Hematology (CMASB): Member, 2003 – present - Shanghai Pharmaceutical Association (SPA): Member, 2011 – present
25
Biography WATTEL Eric Gender: Male Title: Professor of Hematology Email: eric.wattel@chu‐lyon.fr Centre Hospitalier Lyon Sud –Service d’Hématologie, Pavillon Marcel Bérard, Pierre‐Bénite, France Education and Certification: 1980 – 1986: Medical studies, Faculté de Médecine Lille II. 1986 – 1992: Resident, graduated in the Academic Hospitals of Paris 1986 – 1992: Certified in Hematology, Faculté de Médecine Necker‐Enfants‐Malades, Université René
Descartes, Paris V 1990: Certificate of Higher Education (Diplôme d’Etudes approfondies) Health and Life sciences,
Université Pierre et Marie Curie, Paris VI 1992: MD, Thesis of Medicine (Faculté de Médecine Necker‐Enfants‐Malades, Paris V): Silver award 1992: Qualified in Clinical Hematology (Faculté de Médecine Necker‐Enfants‐Malades, Paris V) 1992 – 1994: Assistant‐professor of Clinical Hematology, University Hospitals of Lille 1996: PhD, Health and Life science, University Paris VI (January 1996) 1996: Academic authorization for the teaching and training of pre‐ and post‐doctoral students, University
Lille II (December 1996) 1997: Qualified as University Professor of Hematology (1997) 1999: Hematologist, Lille Academic Hospitals (Bone Marrow Graft Unit, Service des Maladies du Sang,
CHU, Lille), 1999 –: Head Oncovirology and Biotherapy Unit, Centre Léon Bérard, Lyon
Professor of Clinical Hematology, University Claude Bernard, Lyon, Department of Hematology, Lyon University hospital
- Qualified as University Professor of Clinical Hematology, June 1997 - Academic authorization for the teaching and training of pre‐ and post‐doctoral students - Referee for peer‐reviewed general or hematological journals: Leukemia Research, Leukemia,
International Journal of Cancer, Blood, Oncogene, Cancer Research, Clinical Cancer Research, La revue de Médecine Interne, Hématologie, Transfusion,
- Resident, graduated in the Academic Hospitals of Paris (1987‐1992) - Assistant Professor of Oncology (1993‐1994) Clinical Training and Medical Experience: - Intern, Paris Academic Hospitals: Clinical Hematology - Assistant‐Professor, Academic Hospitals – Oct 1992 ‐ Oct 1994: Hematology, LILLE University Hospital
(Pr. Bauters) - Hospital Physician (1994‐) 1994 ‐ 1997: Service of Blood Diseases (Pr Bauters), LILLE University Hospital
Management of various protocols of high‐dose chemotherapy and stem‐cell allograft in acute leukaemia and myelodysplastic syndromes; sterile ward of the Bone marrow Transplantation Unit (Pr. J.P. Jouet)
Nov 97‐Aug 99: Physician in the general ward Sept. 1999‐ Hematology Dept., Hôpital Edouard Herriot (Pr M. Michallet) Research Experience: 1) Clinical Research
French Group Myelodysplasias (GFM): coordinator of clinical protocols for myelodysplastic syndromes. - Stem cell autograft
For myelodysplastic syndromes in complete remission after high‐dose chemotherapy
26
Detection of early relapse and analysis of in vivoclonality after autograft of retrovirally transduced stem‐cells.
- High‐dose chemotherapy after reversion of the mdr phenotype in myelodysplastic syndromes. - Chemotherapy in chronic myelomonocytic leukemia (CMML) of the adult
Hydroxyurea versus etoposide : phase III Trans retinoic acid and hydroxyurea : phase I/II Fludarabine : phase I/II
2) Fundamental Research
Early events in leukemogenesis Peptide‐based biotherapy of hematological malignancies ‐1999:
- Inserm U.524 laboratory, Institute of Cancer Research, Lille (Oncogenesis of Malignant blood diseases, Director: J‐P. Kerckaert)
- Viral Oncogenesis Unit, anticancer Center Oscar Lambret (Director: Pr. Bonneterre). 1999‐ :
- Oncovirology and Biotherapy Unit Unit, anticancer Center Léon Bérard (Director: Pr. Philip). Since January 2000, our group a CNRS team and related to Lyon‐I University (Université Claude Bernard; President: PrDechavanne)
3) Direction of Theses - 0.5 Medical thesesper year, and 0.75 PhD per year since 1997.
Selected Scientific Publications:
- Ducastelle S, Ades L, Gardin C, Dombret H, Prebet T, Deconinck E, Rio B, Thomas X, Debotton S, Guerci A, Gratecos N, Stamatoullas A, Fegueux N, Dreyfus F, Fenaux P, Wattel E. Long‐term follow‐up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Haematologica. 2006;91:373‐376
- Rabaaoui S, Zouhiri F, Lancon A, Leh H, d'Angelo J, Wattel E. Inhibitors of strand transfer that prevent integration and inhibit human T‐cell leukemia virus type 1 early replication. Antimicrob Agents Chemother. 2008;52:3532‐3541.
- Pomier, C., M. T. Alcaraz, C. Debacq, A. Lancon, P. Kerkhofs, L. Willems, E. Wattel, and F. Mortreux. Early and transient reverse transcription during primary deltaretroviral infection of sheep. Retrovirology. 2008;5:16.
- Pomier, C., M. T. Alcaraz, C. Debacq, A. Lancon, P. Kerkhofs, L. Willems, E. Wattel, and F. Mortreux. 2009. A dose‐effect relationship for deltaretrovirus‐dependent leukemogenesis in sheep. Retrovirology6:30.
- Zane, L., D. Sibon, F. Mortreux, and E. Wattel. 2009. Clonal expansion of HTLV‐1 infected cells depends on the CD4 versus CD8 phenotype. Front Biosci14:3935‐41
- Zane, L., D. Sibon, C. Legras, J. Lachuer, A. Wierinckx, P. Mehlen, M. H. Delfau‐Larue, A. Gessain, O. Gout, C. Pinatel, A. Lancon, F. Mortreux, and E. Wattel. 2010. Clonal expansion of HTLV‐1 positive CD8+ cells relies on cIAP‐2 but not on c‐FLIP expression. Virology 407:341‐51.
- Zane, L., D. Sibon, L. Jeannin, M. Zandecki, M. H. Delfau‐Larue, A. Gessain, O. Gout, C. Pinatel, A. Lancon, F. Mortreux, and E. Wattel.2010. Tax gene expression and cell cycling but not cell death are selected during HTLV‐1 infection in vivo. Retrovirology7:17.
- Zane, L., D. Sibon, V. Capraro, P. Galia, M. Karam, M. H. Delfau‐Larue, E. Gilson, A. Gessain, O. Gout, O. Hermine, F. Mortreux, and E. Wattel. 2011. HTLV‐1 positive and negative T cells cloned from infected individuals display telomerase and telomere genes deregulation that predominate in activated but untransformed CD4+ T cells. Int J Cancer Jun 29. doi: 10.1002.
- Sibon, D., G. Cannas, F. Baracco, T. Prebet, N. Vey, A. Banos, C. Besson, S. Corm, M. Blanc, B. Slama, H. Perrier, P. Fenaux, and E. Wattel. 2012. Lenalidomide in lower‐risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis‐stimulating agents. British journal of haematology156:619‐625.
27
Biography XIANG Yong Bing Gender: Male Title: Professor Email: [email protected] Research Interests: - Population‐based cancer registration - Cancer survival analysis - Cancer descriptive epidemiology - Population‐based case‐control and cohort studies on common cancers (e. g. cancers of lung, urinary
bladder, endometrium, liver, colon & rectum, and etc.). - Other activities: e.g. validation on dietary and physical activity in population‐based epidemiological
studies, community‐based cancer control & prevention, etc. Education 1981‐1986 Medicine/Public Health – Anhui Medical University, Hefei, PRC, M.D. 1986‐1989 Epidemiology & Statistics – Shanghai Medical University, Shanghai, PRC MSc. Current Positions 02/06 – Pres. Mentor, School of Public Health, Fudan University (for Ph.D. students) 09/03 – Pres. Mentor, School of Public Health, Shanghai Jiaotong University (for Master students) 03/03 – Pres. Deputy Director, Cancer Institute of Shanghai Jiaotong University 02/01 – Pres. Deputy Director, Shanghai Cancer Institute 07/01 – Pres. Executive Vice Chief, Department of Epidemiology, Shanghai Cancer Institute 12/00 – Pres. Mentor, School of Public Health, Fudan University (for Master students) 12/00 – Pres. Professor, Department of Epidemiology, Shanghai Cancer Institute 12/95 – 11/00 Associate Professor, Department of Epidemiology, Shanghai Cancer Institute 07/89 – 11/95 Assistant Professor, Department of Epidemiology, Shanghai Cancer Institute Committee Members in China 08/10 – Pres. Society of Epidemiology, Chinese Preventive Medical Association 06/10 – Pres. Shanghai Health Education Association 11/08 – Pres. Chinese Anti‐Cancer Association 08/05 – Pres. Shanghai Preventive Medical Association 10/05 – Pres. Society of Cancer Information, Chinese Anti‐Cancer Association 12/04 – Pres. Society of Cancer Registration, Chinese Association of Health Statistics 11/04 – Pres. Vice Chief, Society of Cancer Epidemiology, Chinese Anti‐Cancer Association 11/02 – Pres. Society of Cancer Magazine, Chinese Foundation of Cancer Research 10/00 – Pres. Society of Cancer, Chinese Medical Association 07/99 – Pres. Society of Cancer, Shanghai Medical Association 10/98 – Pres. Society of Cancer Epidemiology, Chinese Anti‐Cancer Association Five Selected Papers: - Wei Zhang, Yong‐Bing Xiang, Hong‐Lan Li, Gong Yang, Hui Cai, Bu‐Tian Ji, Yu‐Tang Gao, Wei Zheng, Xiao
Ou Shu. Vegetable‐based dietary pattern and liver cancer risk. British Journal of Cancer 2012 (under review).
- Jing Gao+, Li Xie+, Wan‐Qing Chen+, Si‐Wei Zhang, Qi‐Jun Wu, Wan‐Shui Yang, Yang Yang, Yu‐Ting Tan, Yong‐Bing Xiang: Incidence trend of primary liver cancer from eleven population‐based cancer registries in China, 1988‐2005. CEBP 2012 (submitted)
- Qi‐Jun Wu, Yang Yang, Emily Vogtmann, Jing Wang, Li‐Hua Han, Hong‐Lan Li, Yong‐Bing Xiang. Cruciferous vegetables intake and the risk of colorectal cancer: a meta‐analysis of observational studies. Annals of Oncology 2012 (accepted).
28
- Gao Shan, Yang Wan‐Shui, Freddie Bray,VaPuthiery, Zhang Wei, Gao Jing, Yong‐Bing Xiang. Declining rates of hepatocellular carcinoma in urban Shanghai: incidence trends, 1976‐2005. European Journal of Epidemiology 2012;27(1):39‐46, DOI: 10.1007/s10654‐011‐9636‐8
- Gao J, Xie L, Yang WS, Zhang W, Gao S, Wang J, Xiang YB. Risk factors of hepatocellular carcinoma ‐ current status and perspectives. Asian Pac J Cancer Prev. 2012;13(3):743‐52.
29
Biography YOU Benoit Gender: Male Title: Assistant Professor, MD, PhD Email: benoit.you@chu‐lyon.fr Education: 2002 – 2008 Medical School.Université Claude Bernard Lyon 1, Lyon, France 2008 – 2010 Clinical & research fellowship in Drug development program of Princess Margaret Hospital,
Toronto, Canada 2010 – 2012 Asssistant‐Professor at Centre Hospitalier Lyon‐Sud (Medical Oncology Department and
Onco‐hematology Phase I Trial Unit), Hospices Civils de Lyon, Lyon, France Research or Clinical Achievements: 2007 Master degree of clinical pharmacology and modelling (AMIT). Université Claude Bernard
Lyon 1, Lyon, France 2008 Certification of Speciality in Medical Oncology. Université Claude Bernard Lyon 1, Lyon,
France Medical Doctor. Université Claude Bernard Lyon 1, Lyon, France 2009 Ontario Institute for Cancer Research Research Fellowship Award Toronto, Ontario,
Canada 2010 American Society of Clinical Oncology Cancer Foundation Merit Award 2011 PhD. Université Claude Bernard Lyon 1, Lyon, France Selected Papers: - Benoit You, Eric X. Chen. Anti‐EGFR monoclonal antibodies for treatment of colorectal cancers:
development of cetuximab and panitumumab. J ClinPharmacol. 2011 Mar 22. [Epub ahead of print] - Benoit You, Anthony Brade, Joan Magalhaes, Lillian L. Siu, Amit Oza, Sonya Lovell, Lisa Wang, David
W. Hedley, Leonardo V. Nicacio, Eric X. Chen. A dose‐escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. Invest New Drugs. 2011 Oct;29(5):996‐1003.
- Benoit You,Marie Pollet‐Villard, Ludivine Fronton, Caroline Labrousse, Anne‐Marie Schott, TouriaHajri, Pascal Girard, Gilles Freyer, Michel Tod, Brigitte Tranchand, Olivier Colomban, Benjamin Ribba, Daniel Raudrant, Jérôme Massardier, Sylvie Chabaud, François Golfier. Predictive values of hCG clearance for risk of methotrexate resistance in low‐risk gestational trophoblastic neoplasias. Ann Oncol 2010; 21(8):1643‐50.
- Benoit You, Ludivine Fronton, Helen Boyle, Jean‐Pierre Droz, Pascal Girard, Brigitte Tranchand, Benjamin Ribba, Michel Tod, Sylvie Chabaud, Henri Coquelin, Aude Fléchon. Predictive Value of Modeled AUCAFP‐hCG, a Dynamic Kinetic Parameter Characterizing Serum Tumor Marker Decline in Patients with Non seminomatous Germ Cell Tumor. Urology 2010; 76(2):423.
- Benoit You, Pascal Girard, Philippe Paparel, Gilles Freyer, Alain Ruffion, Anne Charrié, Emilie Henin, Michel Tod, Paul Perrin. Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy. The prostate 2009;69(12):1325‐33.
- Benoit You, Brigitte Tranchand, Pascal Girard, Claire Falandry, Benjamin Ribba, Sylvie Chabaud, Pierre‐Jean Souquet, Véronique Trillet‐Lenoir, Michel Tod, Gilles Freyer. Etoposide pharmacokinetics and survival in small cell lung cancer patients: results of a multicentre study. Lung Cancer 2008;62:261‐72.
- Benoit You, Paul Perrin, Gilles Freyer, Alain Ruffion, Brigitte Tranchand, Emilie Hénin, Philippe Paparel, Benjamin Ribba, Marian Devonec, Claire Falandry, Cécile Fournel, Michel Tod, Pascal Girard. Advantages of prostate‐specific antigen (PSA) clearance model over simple PSA half‐life computation to describe PSA decrease after prostate adenomectomy. Clin Biochemistry 2008;41(10‐11):785‐95.
30
Biography ZHENG Ying Gender: Female Title: Head of Department E‐mail: [email protected] Research interests: - Cancer descriptive epidemiology, cancer registry - Etiology, prevention, control and long‐term outcomes of breast cancer - Population‐based screening on breast cancer, cervical cancer and colon‐rectal cancer Education: 1996.9 – 1999.7: Master of Medical Science at Shanghai Medical University 1987.9 – 1991.7: B.S. in Medical Science at Shanghai Medical University Research and Public Health Achievements: My major job are planning and managing of Shanghai cancer registry system, developing and maintaining the database, working on data quality control, data management and analysis, and composing the annual Shanghai cancer report. The incidence and survival data from Shanghai Cancer Registry has been published in “Cancer Incidence in Five Continents” since 1970s. As a co‐investigator of 2 population‐based epidemiology studies, A Cohort Study of Ginseng, Soy and other Complementary Medicine use and Breast Cancer Survival and Shanghai Breast Cancer Study, I and my collaborators try to discern the role of dietary, nutrition and life style determinants in breast cancer patients survival in Shanghai women, and to define the risk factors related to breast cancer. Five Selected Papers: - Ying Zheng, Cunxiao Wu, Fan Wu. Status and Trends of Breast Cancer Mortality in Chine Females.
Chinese Journal of Preventive Medicine. 2011,45(2):15.‐154 - Ying Zheng, Chunxiao Wu, Fan Jin, et al. Cancer Incidence Trends from 1973‐2005 in Shanghai[J].
Journey of Diagnostics Concepts & Practice. 2009,8(1):25‐32 - Shu XO, Zheng Y, Cai H, Gu K, Chen Z, Zheng W, Lu W. Soy food intake and breast cancer survival. JAMA
.2009; 302(22):2437‐43. - Vinay Gupta, Kai Gu, Zhi Chen, Wei Lu, Xiao OuShu and Ying Zheng. Concordance of self‐reported and
medical chart information on cancer diagnosis and treatment. BMC Med Res Methodol;2011,11:72 (*Corresponding author)
- Ying Zheng, Cunxiao Wu, Pingping Bao. A study on the morphological verification percentage of cancer cases collected by cancer registry in Shanghai: a current, retrospective and comparative exploration[J]. Journey of Diagnostics Concepts & Practice. 2009,8(3):281‐86
31
Biography Name: ZHU He Gender: Female Email: [email protected] Education: 2006‐2011: Department of Pathology, School of Medicine, University of California‐San Diego: Ph.D. in
Biomedical Sciences Thesis: Dissecting the molecular signaling mechanisms for control of hematopoietic stem cells and
progenitors 2002‐2006: School of Life Science, Fudan University, Shanghai, China: B.Sc. in Biotechnology and
Pharmaceutical Science Research achievements: 2012‐now Associate professor
Renji Stem Cell Research Center, Renji Hospital, Shanghai Jiaotong University, School of Medicine - Signaling control of hematopoietic stem cell and acute myeloid leukemia stem cell self‐
renewal - Shp2 and PI3K/AKT signal crosstalk in erythropoiesis and anemia - Molecular mechanism in prostate stem cell maintenance and prostate cancer
development 2011‐2012 Postdoctorate Research Associate
Department of Biology, University of California‐San Diego - Study of MAPK and PI3K/AKT signal crosstalk in hematopoiesis and leukemogenesis
2006‐2011 Graduate Research Assistant Department of Pathology, School of Medicine, University of California‐San Diego - Functional study of cytoplasmic tyrosine phosphatase Shp2 in hematopoietic stem cell
and leukemia stem cell self renewal - Study of Shp2 and STAT3 signaling crosstalk in the regulation of liver regeneration and
liver cancer development 2005 Research Assistant and Project Participant
Laboratory of Yeast Molecular Genetics Group, Fudan University, Shanghai, China - Research project: The mechanism of ApoCIII gene expression regulated by nuclear
receptor BD73, sponsored by Chun‐Tsung Scholar Program Award 2003‐2004 Research Assistant
Research project: Yeast two‐hybrid screening for BD73‐interacting protein in human fetal liver cDNA library
Honors and Awards: - 2010 Travel Awards:
The 8th International Society of Stem Cell Research (ISSCR) Annual Meeting, San Francisco, California, USA (June 16‐19, 2010)
The 52nd American Society of Hematology (ASH) Annual Meeting and Exposition, Orlando, Florida, USA (December 4‐7, 2010)
- 2006 Honeywell Inc. Research fellowship - 2005 Chun‐Tsung Scholar Program Award for Academic Excellence - 2002‐2004 First‐prize Recipient of Fudan University Honors Scholarship and Excellent Student Award Publications: - Zhu, H.H., Ji, K., Alderson, N., He, Z., Li, S., Liu, W., Zhang, D.E., Li, L., and Feng, G.S.(2011). Kit‐Shp2‐Kit
signaling acts to maintain a functional hematopoietic stem and progenitor cell pool. Blood 117, 5350‐5361.
32
- Zhu, H.H., and Feng, G.S. (2011). The dynamic interplay between a PTK (Kit) and a PTP(Shp2) in hematopoietic stem and progenitor cells. Cell Cycle 10,4253‐4261.
- Bard‐Chapeau, E.A., Li, S., Ding, J., Zhang, S.S., Zhu, H.H., Princen, F., Fang, D.D., Han,T., Bailly‐Maitre, B., Poli, V., et al. (2011). Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 19, 629‐639.
- McPherson, V.A., Sharma, N., Everingham, S., Smith, J., Zhu, H.H., Feng, G.S., and Craig,A.W. (2009). SH2 domain‐containing phosphatase‐2 protein‐tyrosine phosphatase promotes FcεRI‐induced activation of Fyn and Erk pathways leading to TNFα release from bone marrow‐derived mast cells. J Immunology 183, 4940‐4947.
- He, Z., Zhang, S.S., Meng, Q., Li, S., Zhu, H.H., Raquil, M.A., Alderson, N., Zhang, H.,Wu, J., Rui, L., et al. (2012). Shp2 controls female body weight and energy balance by integrating leptin and estrogen signals. Molecular and cellular biology 32, 1867‐1878.
- Huang, H., Woo, A.J., Waldon, Z., Schindler, Y., Moran, T.B., Zhu, H.H., Feng, G.S., Steen, H., and Cantor, A.B. (2012). A Src family kinase‐Shp2 axis controls RUNX1 activity in megakaryocyte and T‐lymphocyte differentiation. Genes & development 26, 1587‐1601.
- He, Z., Zhu, H.H., Wang, J., Ciaraldi, T, Anderson N., Li, S., Raquil M., Ji, K., Wang S.,Henry R., King, P., and Feng, G.S. (2012) Non‐Receptor Tyrosine Phosphatase Shp2Promotes Adipogenesis Through Inhibition of p38 MAP Kinase. P.N.A.S (accepted)
- Yu, J., Zhu, H.H., Zhang, S.S., He, Z., Montminy, M., Davis, R., and Feng, G.S. (2012)Modulation of fatty acid synthase (FASN) degradation by concerted actions of p38, COP1and Shp2. (manuscript in preparation)
Scientific Presentations: - Zhu, H.H. and Feng, G.S. (2010) “Shp2 Regulation of Hematopoietic Stem Cells”, Burnham Institute
Post‐doctor and Graduate Student Forum, Rancho Santa Fe, California, USA (Oral presentation) - Zhu, H.H. and Feng, G.S. (2010) “Shp2 Maintains Normal Function of HSCs and Progenitor Cells”, Salk
Institute Cancer and Stem Cells Symposium, San Diego, California, USA(Poster presentation) - Zhu, H.H., Alderson, N., He, Z., Li, S., Li, L., and Feng, G.S. (2010) “An Essential Role of PTPN11 in
Maintenance of a Functional Hematopoietic Stem Cell Pool”, the 8th International Society of Stem Cell Research (ISSCR) Annual Meeting, San Francisco, California, USA (Poster presentation)
- Zhu, H.H., Ji, K., Alderson, N., He, Z., Li, S., Liu, W., Zhang, D.E., Li, L., and Feng, G.S.(2010) “Coordinated Regulation of Embryonic and Adult Hematopoietic Stem Cell Activity by PTPN11/Shp2”, the 52nd American Society of Hematology Annual Meeting and Exposition, Orlando, Florida, USA (Poster presentation)
- Huang, H., Waldon, Z., Chan, G., Zhu, H.H., Steen, H., Feng, G.S., Neel, B. and Cantor, A.(2010) “Tyrosine Phosphorylation of Runx1 in Megakaryocytes by Src Family Kinases”, the 52nd American Society of Hematology Annual Meeting and Exposition, Orlando, Florida, USA (Poster presentation)
Research Funding: 2013.1‐2016.12 Principal Investigator
Natural Science Foundation of China General Program No. 81270627 2012.10‐2015.9 Principal Investigator
Shanghai City Committee of science and technology Pujiang Talent Program 2012.9‐2016.8 Principal Investigator
Shanghai City Board of education Chengguang Talent program
33
34